Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343226
Status:
COMPLETED
Last Update Posted:
2010-08-25
First Post:
2006-05-30
Brief Title:
An Open Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in de Novo Liver Transplantation
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Open Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in de Novo Liver Transplantation
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of the study areTo compare the renal function of a quadruple immunosuppressive regimen including basiliximab in combination with an optimized cyclosporine dose during the first weeks post-transplantation mycophenolate mofetil and corticosteroids versus a standard triple therapy regimen including cyclosporine standard dose mycophenolate mofetil and corticosteroids
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None